Nasal administration of glucagon combined with dimethyl-β-cyclodextrin: Comparison of pharmacokinetics and pharmacodynamics of spray and powder formulations

International Journal of Pharmaceutics

Volumn 132, Issue 1-2, 1996, Pages 189-194

  Sakr, Farouk M ^a,b  

^a MANSOURA UNIVERSITY   (Egypt)

^b Ministry of Health United Arab Emirates   (United Arab Emirates)

Author keywords

Absorption enhancers; Bioavailability; Dimethyl cyclodextrin; Glucagon; Nasal absorption; Pharmacodynamics; Pharmacokinetics

Indexed keywords

BETA CYCLODEXTRIN DERIVATIVE; DIMETHYL BETA CYCLODEXTRIN; GLUCAGON; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BIOAVAILABILITY; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSAGE FORM; DRUG FORMULATION; GLUCAGON BLOOD LEVEL; GLUCOSE BLOOD LEVEL; INTRANASAL DRUG ADMINISTRATION; MALE; NONHUMAN; PHARMACODYNAMICS; PHARMACOKINETICS; POWDER; PRIORITY JOURNAL; RABBIT; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0030001516     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/0378-5173(95)04385-3     Document Type: Article

References (13)

1. Billington, D. and Coleman, R., Effect of bile salts on human erythrocytes: Plasma membrane vesiculation, phospholipid solubilization and their possible relationships to bile secretion. Biophys. Acta, 509 (1978) 33-47.
2. Elrick, H., Witten, T.A. and Yoshiki, A., Glucagon treatment of insulin reactions. N. Engl. J. Med., 258 (1958) 476-480.
3. Freychet, L., Rizkalla, S.W., Desplanque, N., Basdevant, A., Zirinis, P., Tchobroutsky, G. and Slama, G., Effect of intranasal glucagon on blood glucose levels in healthy subjects and hypoglycemic patients with insulin-dependent diabetes. Lancet, 1 (1988) 1364-1366.
4. Goldgewicht, C., Slama, G. and Tchobroutsky, G., Hypoglycemic reactions in 172 Type 1 (insulin-dependent) diabetic patients. Diabetologia, 24 (1983) 95-99.
5. Hall-Boyer, K., Zaloga, G.R. and Chernow, B., Glucagon: hormone or therapeutic agent? Crit. Care Med., 12 (1984) 584-589.
6. Hirai, S., Okada, H., Yashiki, T. and Uda, Y., European Patent 883302118.1, November 1, 1983.
7. Irie, T., Wakamatsu, K., Arima, H., Aritomi, H. and Uekama, K., Enhancing effects of cyclodextrins on nasal absorption of insulin in rats. Int. J. Pharm., 84 (1992) 129-139.
8. Merkus, F.W.H.M., Verhoef, J.C., Romeijn, S.G. and Schipper, N.G.M., Absorption enhancing effect of cyclodextrins on intranasally administered insulin in rats. Pharm. Res., 8 (1991) 588-592.
9. Ohtani, Y., Irie, T., Uekama, K., Fukunaga, K. and Pitha, J., Differential effects of α-, β-and γ-cyclodextrins on human erythrocytes. Eur. J. Biochem., 186 (1989) 17-22.
10. Pontiroli, A.E., Alberetto, M., Calderara, A., Pajetta, E. and Pozza, G., Nasal administration of glucagon and human calcitonin to healthy subjects: a comparison of powders and spray solutions and of different enhancing agents. Eur. J. Clin. Pharmacol., (1989) 427-430.
11. Pontiroli, A.E., Alberetto, M. and Pozza, G., Metabolic effects of intranasaly administered glucagon: comparison with intramuscular and intravenous injections. Acta Diab. Lat., 22 (1985) 103-109.
12. Schipper, N.G.M., Verhoef, J., Romeijn, S.G. and Merkus, F.W.H.M., Absorption enhancers in nasal insulin delivery and their influence on nasal ciliary functioning. J. Controlled Release, 21 (1992) 173-186.
13. Slama, G., Alamowitch, C., Desplanque, N., Letanoux, M. and Zirinis, P., A new non-invasive method for treating insulin reaction: Intranasal lyophilized glucagon, Diabetologia, 33 (1990) 671-674.